Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MorphoSys AG (OTC: MPSYF).

Full DD Report for MPSYF

You must become a subscriber to view this report.


Recent News from (OTC: MPSYF)

MorphoSys AG Reports Second Quarter 2018 Financial Results
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 1, 2018 / The Company has further advanced its pipeline, including proprietary and partnered programs, and established a U.S. footprint to prepare for commercialization in the U.S. Conference call and webcast (in English) to be held on A...
Source: ACCESSWIRE
Date: August, 01 2018 16:25
MorphoSys to Host Q2 2018 Conference Call on August 2, 2018
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 25, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYF; NASDAQ: MOR) will publish its first six months' 2018 results on August 1 st , 2018 at 10:00 p.m. CEST (4 p.m. EDT; 9 p.m. BST). The Management team of Morpho...
Source: ACCESSWIRE
Date: July, 25 2018 08:30
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s compet...
Source: SeekingAlpha
Date: May, 31 2018 09:04
MorphoSys AG's (MPSYF) CEO Simon Moroney on Q1 2018 Results - Earnings Call Transcript
MorphoSys AG (MPSYF) Q1 2018 Earnings Conference Call May 3, 2018 8:00 AM ET Executives Alexandra Goller - Associate Director Corporate Communications & IR Simon Moroney - Chief Executive Officer Jens Holstein - Chief Financial Officer Analysts Franc Gregori - Trinity D...
Source: SeekingAlpha
Date: May, 03 2018 20:56
MorphoSys AG 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by MorphoSys AG in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 03 2018 09:01
SA Stock To Watch: Netflix To The Rescue?
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Netflix (NFLX) is set to report earnings after the bell on Monday. Analyst have pus...
Source: SeekingAlpha
Date: April, 14 2018 08:32
U.S. IPO Week Ahead: Subscription Unicorn Zuora Kicks Off The Q2 IPO Market
The first two IPOs of the second quarter are targeting a combined $170 million in the week ahead. Subscription billing unicorn Zuora (ZUO) and Alzheimer's disease biotech Alzheon (ALZH) represent the leading sectors from the first quarter. Tech deals are up 20% on average year-to-date; whi...
Source: SeekingAlpha
Date: April, 07 2018 10:18
3 Things In Biotech, March 17: Janssen's Bladder Breakthrough, MorphoSys' Alzheimer's Success, Halozyme's Early Results
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Jan...
Source: SeekingAlpha
Date: March, 18 2018 08:00
MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2017 Results - Earnings Call Transcript
MorphoSys AG (MPSYF) Q4 2017 Results Earnings Conference Call March 13, 2018 9:00 a.m. ET Executives Simon Moroney - Chief Executive Officer Jens Holstein - Chief Financial Officer Malte Peters - Chief Development Officer Alexandra Goller - Associate Director, Corporate Communi...
Source: SeekingAlpha
Date: March, 13 2018 16:42
MorphoSys AG 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by MorphoSys AG in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: March, 13 2018 09:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-10112.00111.50112.10111.502,048
2018-12-07N/A112.30N/AN/A0
2018-12-06N/A112.30N/AN/A0
2018-12-05112.30112.30112.30112.30130
2018-12-04112.30112.30112.30112.30130

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-101002,0484.8828Cover
2018-12-04130130100.0000Short
2018-11-28100100100.0000Short
2018-11-232525100.0000Short
2018-11-16200200100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MPSYF.


About MorphoSys AG (OTC: MPSYF)

Logo for MorphoSys AG (OTC: MPSYF)

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest growing drug classes in human healthcare. lt br / gt lt br / gt Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. lt br / gt lt br / gt Over therapeutic antibody programs based on the company s technologies are currently in development, of which are in clinical trials. The company s most advanced proprietary program is MOR , a first in class antibody against GM CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR is part of MorphoSys s collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR and MOR , both for the treatment of cancer. lt br / gt lt br / gt MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.

 

Contact Information

 

 

Current Management

  • Simon Moroney / CEO
  • Jens Holstein / CFO
  • Claudia GutjahrLoser / VP, Corp. Comm., VP, Investor Rel.
  • Arndt Schottelius / Chief Development Officer

Current Share Structure

  • Market Cap: $2,451,769,673 - 03/16/2018
  • Issue and Outstanding: 22,935,170 - 03/31/2011

 


Recent Filings from (OTC: MPSYF)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 17 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 17 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 26 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 19 2018
Prospectus filed under Rule 424(b)(4)
Filing Type: 424B4Filing Source: edgar
Filing Date: April, 19 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 18 2018

 

 


Daily Technical Chart for (OTC: MPSYF)

Daily Technical Chart for (OTC: MPSYF)


Stay tuned for daily updates and more on (OTC: MPSYF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MPSYF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MPSYF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MPSYF and does not buy, sell, or trade any shares of MPSYF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/